Kazakhstan’s Minister of Science and Higher Education, Sayasat Nurbek, has announced the development of a domestic anti-cancer drug currently undergoing clinical trials.
According to Nurbek, Phase II clinical trials were completed in 2023, and the number of patients participating in the testing has since been significantly expanded.
“At the moment, the drug is being tested on different types of cancer. Last year, trials were conducted exclusively on patients with colorectal cancer. By the end of 2024, we expect the drug to be officially registered and introduced to the market. Preliminary results indicate stable positive dynamics,” the minister stated.
He noted that patients in clinical trials have experienced remissions, with tumor sizes decreasing by an average of 30%.
“By the end of the year, we plan to hold a conference to present the results. The Ministry of Health has been highly supportive, and we have optimized the registration process without violating regulations,” Nurbek added.
The official registration of the drug is expected to be finalized as soon as possible.
Kazakhstan’s development of its first domestically produced anti-cancer drug was first reported in January 2024. Later, Nurbek provided updates on the trial progress and expressed confidence in the drug’s effectiveness.
